SUMMARY
USV has signed an agreement with Wellbeing Nutrition to acquire 79% stake in the D2C nutraceutical brand for ₹1,583 Cr ($174.7 Mn) in an all-cash deal
The majority stake purchase comprises about 35% ownership of Wellbeing Nutrition founder Avnish Chhabria and around 44% from its existing shareholders
USV will be adding Wellbeing Nutrition to its portfolio to extend its commitment from prescription-led care to preventive and lifestyle-focused wellness
Mumbai-based pharmaceutical company USV has signed an agreement with Wellbeing Nutrition
to acquire 79% stake in the D2C nutraceutical brand for ₹1,583 Cr ($174.7 Mn) in an all-cash deal.
The majority stake purchase comprises about 35% ownership of Wellbeing Nutrition founder Avnish Chhabria and around 44% from its existing shareholders, where early backers Fireside Ventures and Hindustan Unilever will exit the startup by selling their stake.
Chhabria, who held about 50% prior to the transaction, will “rollover” to retain stake until March 2028. Besides, the current management will continue to operate the business under the oversight of USV’s board.
Founded in 2019 by Chhabria and Saurabh Kapoor, Wellbeing Nutrition sells vitamins and mineral supplements via its website and retail outlets. Wellbeing Nutrition has raised a total funding of over $12 Mn till date.
It last raised $10 Mn (INR 85 Cr) in Series B funding round, led by Hindustan Unilever Limited (HUL) and Fireside Ventures. It also counts celebrities like actress Rakul Preet and Mira Kapoor among its backers.
Wellbeing Nutrition’s Funding Snapshot
The startup competes with legacy players like Oziva, Gynoveda, Amway, Cureveda and Auric, as well as D2C nutrition startups such as Power Gummies and Fast&Up.
On the financial front, the startup claims to be on track to close FY26 with a net revenue of over ₹260 Cr. Earlier in March 2025, Chhabria told Inc42 that the startup is on track to close FY25 with a revenue of ₹140 Cr.
Post the acquisition, USV will be adding Wellbeing Nutrition to its portfolio to extend its commitment from prescription-led care to preventive and lifestyle-focused wellness.
Founded in 1961, USV is focused on the development of small-molecule active pharmaceutical ingredients along with custom research services for drug development. It is the producer and retailer for medicines like Ecosprin, Tazloc, OnArmi, among others.
“This acquisition dovetails strongly with our strategy to build a future-facing healthcare portfolio that responds to the changing aspirations of Indian consumers. Their success across channels, particularly through their own platform, and their premium, clinically backed portfolio positions us well to accelerate growth while maintaining high standards of quality, compliance, and ethics that USV has been known for,” USV’s managing director Prashant Tewari said.
The healthcare industry is seeing an evident rise in preventive care and wellness treatments today, which has also been attracting investors’ interest in the Indian healthtech startup space.
For instance, pain management device maker CURAPOD secured ₹20 Cr ($2.2 Mn) earlier this week to accelerate its product and app enhancements and scale its manufacturing and go-to-market operations.
Meanwhile, W Health Ventures marked the first close of its second fund at ₹550 Cr ($60.6 Mn), to back around ten startups operating in spaces such as longevity and modern preventive health, geriatrics, and chronic pain management.
]]>
